c-FLIP inhibits caspase 8 activation and apoptosis mediated by death receptors such as Fas and DR5. We studied the effect of c-FLIP on the apoptotic response to chemotherapies used in colorectal cancer (CRC) (5-fluorouracil, oxaliplatin and irinotecan). Simultaneous downregulation of both c-FLIP splice forms c-FLIP L and c-FLIP S with siRNA synergistically enhanced chemotherapy-induced apoptosis in p53 wild-type (HCT116p53
Introduction
Death receptors such as Fas and the tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2) trigger death signals when bound by their natural ligands (Griffith and Lynch, 1998; Nagata, 1999) . Ligand binding to the death receptors leads to recruitment of the adaptor protein Fas-associated death domain (FADD), which in turn recruits caspase 8 (FADD-like interleukin 1b-converting enzyme (FLICE)) zymogens to form death-inducing signalling complexes (DISCs) (Chinnaiyan et al., 1995; Boldin et al., 1996) . Caspase 8 molecules become activated at DISCs and subsequently activate proapoptotic downstream molecules. A key inhibitor of death receptor signalling is c-FLIP, which inhibits caspase 8 recruitment and processing at the DISC (Krueger et al., 2001) . Differential splicing gives rise to long (c-FLIP L ) and short (c-FLIP S ) forms of c-FLIP. Both c-FLIP splice variants bind to FADD within the DISC. c-FLIP S directly inhibits caspase 8 activation at the DISC, whereas c-FLIP L is first processed to a truncated p43 form by caspase 8 that inhibits the complete processing of caspase 8 to its active subunits.
The fluoropyrimidine 5-fluorouracil (5-FU) has been the mainstay of colorectal cancer (CRC) therapy for over 40 years . The topoisomerase-1 inhibitor irinotecan (CPT-11) and the DNA damaging agent oxaliplatin (OXA) are now being used in conjunction with 5-FU for the treatment of metastatic CRC, having demonstrated improved response rates compared to treatment with 5-FU alone (40-50% compared to 10-15%) (Douillard et al., 2000; Giacchetti et al., 2000) . Despite these improvements, the vast majority of responding patients relapse, with median survival times of only 22-24 months. So, clearly, new approaches are needed for the treatment of this disease. The identification of molecules that control cancer cell death in response to chemotherapy is of vital importance, as such molecules may constitute important clinical predictive markers of response to chemotherapy and/or novel therapeutic targets. In this study, we evaluated the role of c-FLIP in regulating apoptosis of CRC cells in response to chemotherapy.
Results

siRNA targeting of c-FLIP sensitizes HCT116p53
þ / þ cells to chemotherapy We previously identified c-FLIP as a 5-FU-inducible gene by DNA microarray profiling (Maxwell et al., 2003) . In order to study the role of c-FLIP in regulating the response of CRC cells to chemotherapy, we generated siRNAs to target c-FLIP. Of several siRNAs tested, one c-FLIP-targeted (FT) siRNA potently downregulated expression of both c-FLIP splice variants in the nanomolar range ( Figure 1a ). The FT siRNA sensitized HCT116p53 þ / þ cells to apoptosis induced by the Fas agonist CH-11 and rTRAIL, as assessed by PARP cleavage (Figure 1a ) and cell cycle analyses, as indicated by the percentage of cells in the sub-G1 apoptotic fraction (Figure 1b) . FT siRNA also sensitized a p53 null HCT116 daughter cell line to rTRAIL and to a lesser extent CH-11 (Figure 1a and b). These results were further confirmed by Crystal Violet cell viability assays (Figure 1c) and are consistent with the concept that c-FLIP is an inhibitor of death receptormediated apoptosis.
Notably, cotreatment with FT siRNA and 5-FU for 48 h resulted in a supra-additive increase in apoptosis as assessed by flow cytometry, with B60% of cells in the sub-G1 apoptotic fraction compared to B23% in 5-FUtreated cells transfected with the control nonsilencing siRNA (SC) (Figure 2a) . Similar results were obtained in cells cotreated with FT siRNA and both OXA and CPT-11 (Figure 2a) . The flow cytometry data were supported by Western blot analyses, with potent activation of caspase 8 and PARP cleavage observed in cells cotreated with FT siRNA and 5-FU (Figure 2b ). Similar results were again obtained in cells cotreated with FT siRNA and both OXA and CPT-11 ( Figure 2b ). We also carried out cell viability assays to determine whether the interactions between FT siRNA and chemotherapy were synergistic. These assays indicated that cotreatment with FT siRNA and 5-FU resulted in synergistic decreases in cell viability according to the definitions of Chou and Talalay (1984) , with combination index (CI) values of o1 for 8/9 concentrations ( Figure 2c) . Similarly, cotreatment with FT siRNA and both OXA and CPT-11 resulted in synergistic decreases in cell viability for all concentrations examined ( Figure 2c ). SC had no effect on cell viability in the presence or absence of any of the drugs (data not shown). Collectively, these results indicate that downregulation of c-FLIP dramatically sensitizes HCT116p53 þ / þ cells to chemotherapyinduced apoptosis.
Effect of c-FLIP on chemosensitivity in a panel of CRC cell lines In order to determine whether downregulation of c-FLIP would also sensitize p53 null HCT116 cells to chemotherapy-induced apoptosis, we transfected these cells with FT siRNA and cotreated them with chemotherapy. The p53 null cells expressed higher levels of both c-FLIP splice forms than p53 wild-type (wt) cells, but expression was effectively downregulated by 1 nM FT siRNA (Figure 3a) . Cotreatment of FT siRNAtransfected HCT116p53
À/À cells with 5 mM 5-FU significantly increased apoptosis compared to cells cotreated with 5-FU and SC (Figure 3b ). Downregulating c-FLIP expression in HCT116p53 À/À cells also significantly increased apoptosis in response to both OXA and CPT-11 (Figure 3b ). These results indicate that downregulating c-FLIP expression also significantly sensitized p53 null HCT116 cells to chemotherapy-induced apoptosis.
In order to rule out the possibility that the effects of c-FLIP were specific to the HCT116 models, we extended these studies into two further CRC cell line models: the p53 wt RKO cell line and the p53 mutant H630 cell line. Each cell line expressed both c-FLIP splice forms, and FT siRNA downregulated c-FLIP protein in both lines and 0.5 nM FT ( þ ) siRNA in the presence and absence of 100 ng/ ml CH-11 or 2.5 ng/ml rTRAIL for 24 h. (b) Flow-cytometric analysis of apoptosis in HCT116p53 þ / þ and HCT116p53 À/À cells transfected with 0.5 nM FT or 0.5 nM SC siRNA in the presence and absence of 100 ng/ml CH-11 or 2.5 ng/ml rTRAIL for 24 h. The percentage of cells in the sub-G1 apoptotic fraction for each treatment group is indicated. (c) Crystal violet cell viability assays in HCT116p53 þ / þ and HCT116p53 À/À cells transfected with 0.5 nM FT or 0.5 nM SC siRNA and treated with 100 ng/ml CH-11 or 2.5 ng/ml rTRAIL for 24 h. c-FLIP inhibits chemotherapy-induced apoptosis DB Longley et al ( Figure 3a) . As in the HCT116 cell lines, downregulation of c-FLIP sensitized both cell lines to apoptosis induced by 5-FU, OXA and CPT-11 (Figure 3b ). In each case, the effect of cotreatment with chemotherapy and FT siRNA was more than additive.
c-FLIP L overexpression inhibits chemotherapy-induced apoptosis As a complementary approach to downregulating c-FLIP expression, we generated HCT116p53 þ / þ cell lines that overexpressed c-FLIP L or c-FLIP S . The HFL17 and HFL24 cell lines both overexpressed c-FLIP L by B4-fold compared to cells transfected with a LacZexpressing construct (HLacZ), while the HFS19 and HFS44 cell lines overexpressed c-FLIP S by B7-and B10-fold, respectively, compared to the control cell line (Figure 4a ). Flow cytometry revealed that c-FLIP L overexpression had a marked effect on chemotherapyinduced apoptosis (Figure 4b ). For example, the levels of apoptosis induced in response to 5-FU was significantly reduced in the two c-FLIP L -overexpressing lines compared to the control cell line, with B15% of HFL17 cells and B17% of HFL24 cells in the sub-G 1 apoptotic fraction compared to B41% in the HLacZ cell line (Figure 4b ). In contrast, c-FLIP S overexpression did not inhibit 5-FU-induced apoptosis in the HFS19 and HFS44 cell lines; in fact, the levels of apoptosis in the HFS19 and (in particular) HFS44 cell lines were somewhat higher than in the HLacZ control cell line. Similarly, overexpression of c-FLIP L significantly decreased OXA-induced apoptosis, whereas c-FLIP S overexpression failed to inhibit OXA-induced apoptosis (Figure 4b ). c-FLIP L overexpression also significantly inhibited CPT-11-induced cell death. Apoptosis in response to CPT-11 was somewhat reduced in the c-FLIP S -overexpressing cell lines, although to a lesser extent than in the c-FLIP L -overexpressing cell lines (Figure 4b ).
To confirm that the increased resistance of HFL17 cells to chemotherapy was due to c-FLIP L overexpression, we developed a specific c-FLIP L -targeted siRNA (FL) that downregulated c-FLIP L expression in HFL17 cells to levels similar to those observed in the parental cell line (Figure 4c) . Importantly, transfection of HFL17 À/À cells were cotreated with 5 mM 5-FU, 5 mM OXA or 2.5 mM CPT-11. RKO cells were cotreated with no drug, 5 mM 5-FU, 1 mM OXA or 2.5 mM CPT-11. H630 cells were cotreated with no drug, 5 mM 5-FU, 2.5 mM OXA or 1 mM CPT-11. The percentage of cells in the sub-G1 apoptotic fraction for each treatment group is indicated. c-FLIP inhibits chemotherapy-induced apoptosis DB Longley et al cells with FL siRNA re-sensitized them to chemotherapy-induced apoptosis (Figure 4c ), indicating that the increased chemoresistance of these cells was due to c-FLIP L overexpression. As c-FLIP L has been described as a caspase 8 inhibitor (Krueger et al., 2001) , we analysed whether inhibiting caspase 8 would have the same effect as c-FLIP L overexpression on chemotherapy-induced apoptosis. To do this, we used a caspase 8-targeted siRNA, which efficiently downregulated the procaspase 8 zymogen and attenuated rTRAIL-induced apoptosis (Figure 4d ). Similar to the effects of c-FLIP L overexpression, knockdown of caspase 8 inhibited apoptosis induced by 5-FU, OXA and (to a lesser extent) CPT-11 (Figure 4d ). These results suggest that c-FLIP L overexpression inhibits caspase 8-mediated chemotherapy-induced cell death.
Effect of specific knockdown of c-FLIP L or c-FLIP S on chemotherapy-induced apoptosis
The data from the c-FLIP-overexpressing cell lines suggested that c-FLIP L was a more important regulator of chemoresistance than c-FLIP S (Figure 4b ). So, we used the c-FLIP L -specific (FL) siRNA and a c-FLIP Sspecific (FS) siRNA to analyse the effect of specifically downregulating each splice form on chemosensitivity in the parental HCT116p53
cell line. FL and FS siRNAs specifically downregulated expression of the appropriate splice form without affecting the other (Figure 5a ). PARP cleavage analysis demonstrated that combined treatment with FL siRNA and each chemotherapy for 24 h enhanced apoptosis in HCT116p53 þ / þ cells to a similar degree as the dual targeted FT siRNA (Figure 5b ). In contrast, FS siRNA did not enhance 5-FU-or CPT-11-induced apoptosis after 24 h, and only moderately enhanced OXA-induced cell death (Figure 5b) . Furthermore, cotreatment with each chemotherapy and FL siRNA resulted in highly synergistic decreases in cell viability (Figure 5c ), similar to the effects of the dual-targeted FT siRNA (Figure 2c ). These data suggest that downregulation of c-FLIP L is sufficient to recapitulate the effects of downregulating both splice variants and that, of the two splice forms, c-FLIP L is the more critical regulator of CRC cell death in response to chemotherapy.
The effects of c-FLIP downregulation on chemotherapyinduced apoptosis are caspase 8-dependent We next assessed whether the effects of knocking down c-FLIP expression on chemotherapy-induced apoptosis were a result of enhanced death receptor signalling. Firstly, we assessed the requirement for caspase 8 in this process using a caspase 8-targeted siRNA. The caspase 8-targeted siRNA potently downregulated procaspase 8 expression and the levels of p41/43-and p18-caspase 8 in Similar results were obtained with the caspase 8 inhibitor Z-IETD-FMK, which also attenuated PARP cleavage induced by chemotherapy and FT siRNA (data not shown). These results were confirmed by flow cytometry, which demonstrated that apoptosis induced by FT siRNA and chemotherapy was abrogated when caspase 8 activation was blocked using caspase 8-targeted siRNA (Figure 6b ). These results indicate that activation of caspase 8 is a key step in the onset of apoptosis induced by FT siRNA and chemotherapy.
The effects of c-FLIP downregulation on chemotherapy-induced apoptosis are DR5-dependent c-FLIP inhibits caspase 8 activation at DISCs formed by both Fas and the TRAIL receptors DR4 and DR5; therefore, we investigated the roles of these death receptors in chemotherapy-induced apoptosis. DR4 was not expressed on the cell surface of HCT116 cells, either constitutively or in response to chemotherapy (data not shown). However, DR5 was highly expressed and efficiently knocked down using a DR5-specific siRNA (Figure 7a ). Fas was expressed at a lower level than DR5 on the cell surface of HCT116 cells, but was highly induced by chemotherapy treatment (Figure 7a) . A Fas-targeted siRNA was developed that potently knocked down Fas cell surface expression both in the presence and absence of chemotherapy (Figure 7a ). Interestingly, we found that downregulating DR5 cell surface expression significantly reduced 5-FU-and OXA-induced apoptosis (by B12 and B14%, respectively) and moderately reduced CPT-11-induced apoptosis (by B5%) (Figure 7b ). These results indicate that chemotherapy-induced apoptosis in HCT116p53
cells is mediated at least in part through DR5. In contrast, downregulating cell surface Fas expression did not inhibit chemotherapy-induced apoptosis (Figure 7b ). Most importantly, we found that downregulating DR5 but not Fas significantly attenuated apoptosis induced by cotreatment with FT siRNA and each chemotherapy, as assessed by PARP cleavage (Figure 7c , compare lanes 10, 11 and 12; 16, 17 and 18; and 22, 23 and 24) . Furthermore, downregulating DR5 but not Fas significantly attenuated processing of procaspase 8 to p41/43-and p18-caspase 8 in cells cotreated with FT siRNA and chemotherapy c-FLIP inhibits chemotherapy-induced apoptosis DB Longley et al (Figure 7c ). Together with the data presented in Figure 6 , these results indicate that apoptosis induced by chemotherapy following knockdown of c-FLIP is highly dependent on DR5-mediated activation of caspase 8.
Effects of c-FLIP downregulation on chemotherapyinduced apoptosis are death ligand-independent
Death receptor-mediated apoptosis is normally activated following ligation of the receptors by their respective ligands: TRAIL in the case of DR4 and DR5, and Fas ligand (FasL) in the case of Fas. To examine the requirement for TRAIL and Fas Ligand (FasL) in inducing apoptosis in response to FT siRNA and chemotherapy, we used neutralizing antibodies against each death ligand. Firstly, working concentrations for each neutralizing antibodies were determined.
The anti-TRAIL antibody (AT) was used at 100 ng/ml, as this concentration attenuated apoptosis induced by rTRAIL (Figure 8a ). The anti-FasL antibody (NOK-1) was also used at 100 ng/ml, as this concentration completely blocked the additional apoptosis induced by addition of rFasL to OXA-treated cells (Figure 8a ). As expected, given the lack of effect of Fas-targeted siRNA (Figure 7c ), NOK-1 had no effect on FT siRNA/ chemotherapy-induced apoptosis (Figure 8b) . However, surprisingly, we found that the anti-TRAIL neutralizing antibody also had no effect on PARP cleavage and caspase 8 activation in FT siRNA and chemotherapy cotreated cells (Figure 8b ). Furthermore, HCT116p53 þ / þ cells did not express detectable levels of membranebound TRAIL (mTRAIL), either constitutively or in response to chemotherapy (Figure 8c) . Similarly, constitutive levels of membrane-bound FasL (mFasL) were c-FLIP inhibits chemotherapy-induced apoptosis DB Longley et al low and were not induced in response to 5-FU and OXA, although they were moderately induced in response to CPT-11 (Figure 8c ). Collectively, these results indicate that c-FLIP inhibits TRAIL-independent, DR5-mediated apoptosis in response to chemotherapy, and that downregulation of c-FLIP potently sensitizes the cells to chemotherapy-induced apoptosis via this pathway.
Discussion
Death receptor signalling is regulated by c-FLIP, which has been reported to inhibit caspase 8 activation at DISCs formed following receptor ligation (Krueger et al., 2001) . Initially, both proapoptotic and antiapoptotic effects were proposed for c-FLIP; however, data from cell lines stably overexpressing c-FLIP and from mice deficient in c-FLIP support an antiapoptotic function for c-FLIP (Irmler et al., 1997; Yeh et al., 2000) . More recently, Micheau et al. (2002) reported that c-FLIP L (but not c-FLIP S ) actually promotes the first cleavage step of caspase 8 activation from the pro-form to the p41/43 form, but prevents further cleavage to the active p10 and p18 subunits. Interestingly, they propose that the DISC-bound c-FLIP Lcaspase 8 heterocomplex is a partially active protease restricted to the cell membrane, which can act on localized substrates. Our results demonstrate an antiapoptotic role for c-FLIP in CRC cells, as siRNA targeting of c-FLIP sensitized each of the four CRC cell lines examined to chemotherapy-induced apoptosis. Furthermore, we found that overexpression of c-FLIP L protected HCT116 cells from chemotherapy-induced apoptosis.
Numerous studies have demonstrated that c-FLIP overexpression confers resistance to death receptormediated apoptosis (Irmler et al., 1997; Scaffidi et al., 1999; Nam et al., 2003) . However, relatively few studies have examined the effect of elevated c-FLIP expression on apoptosis induced by chemotherapy. Micheau et al. (1999) c-FLIP inhibits chemotherapy-induced apoptosis DB Longley et al apeutic drugs (Matta et al., 2002; Conticello et al., 2004) . In contrast, c-FLIP overexpression did not inhibit chemotherapy-induced apoptosis in Jurkat T cells (Kataoka et al., 1998) . Our findings indicate that overexpression of c-FLIP L inhibits apoptosis of CRC cells in response to the chemotherapeutic agents used in the treatment of CRC. This has particular clinical relevance given the high incidence of c-FLIP L overexpression observed in colon cancer (Ryu et al., 2001) . Interestingly, c-FLIP S overexpression failed to protect CRC cells from 5-FU-and OXA-induced apoptosis, and only moderately protected against CPT-11-induced apoptosis. In fact, the apoptosis in the c-FLIP S -overexpressing cell lines following 5-FU and OXA treatment was somewhat enhanced compared to the control cell line, in particular for the HFS44 cell line. It is possible that the relatively high levels of c-FLIP S in the two c-FLIP S -overexpressing cell lines (in particular HFS44) may be superphysiological and promote DISC-independent clustering and activation of caspase 8. In contrast, the levels of c-FLIP L overexpression in the HFL17 and HFL24 cell lines (B4-fold) are similar to the levels of overexpression observed by Ryu et al. (2001) in colonic tumours. The different effects of overexpressing each splice form may be due to c-FLIP L being a more potent inhibitor of death receptor-mediated apoptosis (Irmler et al., 1997) . In addition, the enhanced chemoresistance in the c-FLIP L -overexpressing lines may be due at least in part to c-FLIP L -activating intrinsic survival pathways such as those mediated by NF-kB and PI3 kinase Kataoka and Tschopp, 2004) . Several studies have demonstrated that downregulating c-FLIP sensitizes various tumour cells to apoptosis induced by Fas agonists and TRAIL (Fulda et al., 2000; Poulaki et al., 2002; Mathas et al., 2004; Santiago et al., 2004) . However, we are aware of only one other study that has demonstrated that downregulating c-FLIP sensitizes cancer cells to chemotherapy in the absence of cotreatment with a death receptor ligand. This study demonstrated that downregulation of c-FLIP in cisplatin-sensitive and -resistant HeLa cervix carcinoma cells using antisense oligonucleotides promoted cell death in response to cisplatin; however, the effect was much greater in the resistant cell line that overexpressed c-FLIP (Kamarajan et al., 2003) . Our study indicates that downregulating c-FLIP in a panel of CRC cell lines increases their sensitivity to a range of cytotoxic drugs with differing mechanisms of action. Furthermore, downregulation of c-FLIP L recapitulated the effects of knocking down both splice forms, again suggesting that c-FLIP L is the more important mediator of resistance to chemotherapy in CRC cells. Our results indicate that targeting c-FLIP (in particular c-FLIP L ) enhances CRC cell death in response to chemotherapies used to treat this disease, suggesting that c-FLIP may represent a new therapeutic target for the treatment of CRC.
We found that the mechanism by which apoptosis was activated by chemotherapy in CRC cells following downregulation of c-FLIP was caspase 8-dependent. Furthermore, overexpression of c-FLIP L inhibited chemotherapy-induced apoptosis to a similar extent as siRNA-mediated downregulation of procaspase 8. These results are consistent with the reported role of c-FLIP as a caspase 8 inhibitor, and suggest that the ratio of c-FLIP to procaspase 8 is a key factor in determining the onset of apoptosis following chemotherapy.
Examination of the roles of Fas and DR5 in regulating chemotherapy-induced cell death in CRC cells revealed that DR5 is an important mediator of apoptosis following chemotherapy, in particular in response to 5-FU and OXA. These results are consistent with those of Wang and El-Deiry (2004) , who recently reported that inducible silencing of DR5 in HCT116 cells decreased sensitivity to 5-FU. However, downregulation of Fas failed to inhibit chemotherapyinduced cell death, despite the fact that Fas was potently upregulated by chemotherapy in the HCT116 cell line. Importantly, we found that the synergistic effects of knocking down c-FLIP on chemotherapy-induced apoptosis were mediated predominantly through DR5 rather than Fas. Although DR5 knockdown did not completely abrogate the induction of apoptosis in FT siRNA/chemotherapy cotreated cells, this may be due to the fact that cells transfected with 10 nM DR5-targeted siRNA still expressed significant levels of cell surface DR5 (B20%; Figure 7a ). Indeed, DR5 siRNA-transfected cells were still sensitive to rTRAIL (albeit to a lesser extent than nontransfected cells, data not shown), indicating that DR5-dependent cell death was still functional in these cells. However, it is possible that other caspase 8-dependent mechanisms may also partially mediate the observed effects of FT siRNA on chemotherapy-induced cell death, for example, a recent study described death receptor-and death ligandindependent DISCs induced by viral double-stranded RNAs (Iordanov et al., 2005) .
Classically, activation of death receptor signalling is triggered following binding of the receptors by their ligands, which leads to receptor trimerization and recruitment of the components of the DISC. However, several studies have indicated that death ligand-independent activation of Fas can occur in response to a variety of stimuli, including anticancer drugs (Aragane et al., 1998; Beltinger et al., 1999; Micheau et al., 1999; Gniadecki, 2004) . Indeed, Micheau et al. (1999) found that cisplatin stimulated Fas receptor clustering and FADD recruitment in the absence of FasL in HCT116 and HT29 CRC cell lines. Recent evidence suggests that members of the TNF receptor family are expressed as pre-associated homotrimers on the cell surface of resting cells (Chan et al., 2000) . In the case of Fas, various stimuli have been shown to induce superclustering of these pre-associated homotrimers and apoptotic signalling in a FasL-independent manner (Aragane et al., 1998; Micheau et al., 1999; Gniadecki, 2004; Kim et al., 2004) . Although we found that enhanced cell death in response to chemotherapy following c-FLIP knockdown was DR5-dependent, it was not affected by TRAIL neutralizing antibodies. Furthermore, membrane-bound TRAIL was not detected on these CRC cells. In addition, we have found that chemotherapy-induced apoptosis in the absence of c-FLIP knockdown is also not affected by TRAIL neutralizing antibodies (data not shown), despite being partly DR5-dependent. To our knowledge, this is the first study to implicate TRAILindependent DR5-mediated apoptotic signalling as a mechanism of chemotherapy-induced cell death. However, a recent study reported that c-FLIP L interacts directly with DR5 in a TRAIL-and FADD-independent manner, and that disruption of this interaction results in TRAIL-independent apoptosis (Jin et al., 2004) . The authors suggest that c-FLIP L inhibits ligand-independent recruitment of FADD and caspase 8 to DR5. It is possible that c-FLIP L inhibits ligand-independent recruitment of FADD and caspase 8 to the DR5 DISC in CRC cells treated with chemotherapy, and that downregulating c-FLIP L sensitizes the cells to undergo apoptosis by this mechanism.
Our findings have direct clinical relevance as 5-FU/ leucovorin/OXA (FOLFOX) and 5-FU/leucovorin/ CPT-11 (FOLFIRI) combination chemotherapies are currently widely used in the treatment of advanced CRC, and FOLFOX has recently been demonstrated to improve 3-year survival compared to 5-FU/leucovorin in the adjuvant setting of the disease (78.2 versus 72.9%, P ¼ 0.002) (Andre et al., 2004) . Furthermore, clinical studies have demonstrated significantly elevated c-FLIP expression in colorectal and gastric tumours (Ryu et al., 2001; Zhou et al., 2004) , suggesting that c-FLIP may be a relevant clinical target not only in CRC but also in gastric cancer, where 5-FU-based chemotherapy regimens are also used. Moreover, our data suggest that c-FT therapeutic strategies may be effective against colorectal tumours irrespective of p53 mutational status. The present study suggests that c-FLIP may represent an important clinical marker of drug resistance in CRC, and that targeting c-FLIP in combination with standard chemotherapies has therapeutic potential for the treatment of this disease.
Materials and methods
Materials
The Fas agonistic antibody CH-11 was obtained from MBL International (Woburn, USA), and rTRAIL was obtained from Calbiochem (San Diego, USA). The caspase 8 inhibitor Z-IETD-FMK was purchased from Calbiochem. Isotype control and anti-Fas FITC-conjugated mouse IgG1 monoclonal antibodies were obtained from DakoCytomation (Cambridgeshire, UK). Isotype control, anti-DR5, anti-FasL and anti-TRAIL PE-conjugated mouse IgG1 monoclonal antibodies were obtained from eBioscience (San Diego, CA, USA). Anti-TRAIL neutralizing antibody was obtained from (R&D Systems, Minneapolis, MN, USA) and anti-FasL antibody was obtained from Pharmingen BD Biosciences (Oxford, UK).
Cell culture
All cells were maintained in 5% CO 2 at 371C. H630 and RKO cells were maintained in DMEM with 10% dialysed bovine calf serum supplemented with 1 mM sodium pyruvate, 2 mM Lglutamine and 50 mg/ml penicillin/streptomycin (all from Life Technologies Inc., Paisley, UK). HCT116p53
and HCT116p53 À/À isogenic human CRC cells were kindly provided by Professor Bert Vogelstein (John Hopkins University, Baltimore, MD, USA). Both HCT116 cell lines were grown in McCoy's 5A medium (Life Technologies Inc.) supplemented with 10% dialysed foetal calf serum, 50 mg/ml penicillin-streptomycin, 2 mM L-glutamine and 1 mM sodium pyruvate.
Generation of c-FLIP-overexpressing cell lines c-FLIP L and c-FLIP S coding regions were PCR amplified and ligated into the pcDNA/V5-His TOPO vector according to the manufacturer's instructions (Life Technologies Inc.). HCT116p53 þ / þ cells were cotransfected with 10 mg of each c-FLIP expression construct and 1 mg of a construct expressing a puromycin resistance gene (pIRESpuro3, Clontech) using GeneJuice (Merck Biosciences, Darmstadt, Germany). Stably transfected HCT116p53
þ / þ cells were selected and maintained in medium supplemented with 1 mg/ml puromycin (Life Technologies Inc.).
Western blotting
Western blots were performed as described previously (Longley et al., 2002) . Caspase 8 (Oncogene Research Products, Darmstadt, Germany and Alexis, Bingham, UK), PARP (Pharmingen, BD Biosciences, Oxford, UK) and c-FLIP (NF-6, Alexis) mouse monoclonal antibodies were used in conjunction with a horseradish peroxidase (HRP)-conjugated sheep anti-mouse secondary antibody (Amersham, Little Chalfont, Buckinghamshire, UK). Equal loading was assessed using a b-tubulin mouse monoclonal primary antibody (Sigma, Poole, Dorset, UK).
Cell viability assays
Cell viability was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) assay (Mosmann, 1983) . To assess chemotherapy/siRNA interactions, 2500-5000 cells were seeded per well on 96-well plates. After 24 h, the cells were transfected with siRNA and treated with a range of concentrations of each drug 4 h after transfection. After 72 h, MTT (0.5 mg/ml) was added to each well and the cells were incubated at 371C for a further 2 h. The culture medium was removed and formazan crystals reabsorbed in 200 ml DMSO. Cell viability was determined by reading the absorbance of each well at 570 nm using a microplate reader (Molecular Devices, Wokingham, UK). Cell viability was also assessed by Crystal Violet assay. Cells were seeded at 10 000 cells per well on 12-well plates. The following day, the cells were transfected with siRNA for 4 h and then treated with rTRAIL or CH-11 for a further 20 h. Cells were fixed in methanol and stained with 0.01% Crystal Violet for 5 min. Each cell viability experiment was carried out at least three times. Representative results are presented.
Flow cytometry DNA content of harvested cells was evaluated after propidium iodide staining of cells using the EPICS XL Flow Cytometer (Coulter, Miami, FL, USA). Apoptosis was determined by evaluating the percentage of cells with DNA content o2 N. To examine cell surface expression of Fas, DR5, FasL and TRAIL, FITC-conjugated anti-Fas (DakoCytomation) and PE-conjugated anti-DR5, anti-FasL and anti-TRAIL (eBioscience) mouse IgG1 monoclonal antibodies were used in conjunction with the appropriate isotype control antibodies. Cells were collected and washed twice in PBS before incubation with antibody (1/20 dilution) at 41C for 30 min.
Following incubation, the cells were washed twice with PBS containing 2% bovine serum albumin and fixed in 0.3 ml 4% paraformaldehyde. Samples were then analysed on the EPICS XL Flow Cytometer. Each flow cytometry experiment was carried out at least three times. Representative results are presented.
siRNA transfections siRNAs were designed using the Invitrogen RNAi designer tool (https://rnaidesigner.invitrogen.com/rnaiexpress/) to downregulate both c-FLIP splice variants (FT), or to specifically downregulate the long form (FL) or the short form (FS). This tool was also used to design an siRNA to downregulate Fas. A previously published DR5 siRNA sequence was used (Wang and El-Deiry, 2004) . Caspase 8 siRNA was purchased from the Qiagen siRNA library (Qiagen, West Sussex, UK). The FT siRNA sequence used was: AAG CAG TCT GTT CAA GGA GCA. The FL siRNA sequence used was: AAG GAA CAG CTT GGC GCT CAA. The FS siRNA sequence used was: AAC ATG GAA CTG CCT CTA CTT. The Fas sequence used was: AAG CCC TGT CCT CCA GGT GAA. The SC sequence used was: AAT TCT CCG AAC GTG TCA CGT. FT, FL, FS, DR5, Fas and SC siRNAs were obtained from Dharmacon (Lafayette, CO, USA). siRNA transfections were performed on subconfluent cells incubated in unsupplemented Optimem medium using the oligofectamine reagent (both from Life Technologies Inc.) according to the manufacturer's instructions.
Statistical analyses
The nature of the interaction between the chemotherapeutic drugs and FT siRNAs was determined by calculating the CI according to the method of Chou and Talalay (1984) . CI values were calculated from isobolograms generated using the CalcuSyn software programme (Microsoft Windows). According to the definitions of Chou and Talalay, a CI value of 0.85-0.9 is slightly synergistic, 0.7-0.85 is moderately synergistic, 0.3-0.7 is synergistic and 0.1-0.3 is strongly synergistic. An unpaired two-tailed t-test was used to determine the significance of changes in levels of apoptosis between different treatment groups. All changes in levels of apoptosis that are described as significant had P-values that were o0.001.
